The Clinical Impact of the Sum of the Maximum Standardized Uptake Value on the Pretreatment with F-18-FDG-PET/CT in Small-Cell Lung Cancer
- Authors
- Go, Se-Il; Song, Haa-Na; Kang, Jung-Hun; Kang, Myung Hee; Kim, Moon Jin; Jung, Jaehoon; Chung, Soon Il; Choi, Bong-Hoi; Hwang, In-Gyu; Kim, Seok-Hyun; Ling, Hui; Lee, Gyeong-Won
- Issue Date
- Jan-2014
- Publisher
- KARGER
- Keywords
- Platinum; Positron emission tomography; Small-cell lung carcinoma; Survival
- Citation
- ONCOLOGY, v.86, no.1, pp 1 - 9
- Pages
- 9
- Journal Title
- ONCOLOGY
- Volume
- 86
- Number
- 1
- Start Page
- 1
- End Page
- 9
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/13909
- DOI
- 10.1159/000357136
- ISSN
- 0030-2414
1423-0232
- Abstract
- Objectives: The aim of this study was to investigate the clinical significance of the sum of the maximum standardized uptake value (sumSUV(max)) on pretreatment positron emission tomography/computed tomography (F-18-FDG-PET/CT) in newly diagnosed small-cell lung cancer (SCLC). Methods: We retrospectively analyzed 145 SCLC patients from March 2005 to June 2013 who underwent pretreatment F-18-FDG-PET/CT. The sumSUV(max) was assessed in all malignant lesions up to a maximum of 5 lesions and a maximum of 2 lesions per organ according to RECIST 1.1. Results: A significant difference was found between the low and high sumSUV(max) groups (low vs. high sumSUV(max), 91.5 vs. 77.3%; p = 0.018) in the response rate (RR) following frontline platinum-based chemotherapy. The group with low sumSUV(max) showed significantly better overall survival (OS; p < 0.001) as well as better progression-free survival (PFS; p < 0.001) compared with the group with high sumSUV(max). Moreover, multivariate analysis revealed that a high sumSUV(max) alone was an independent poor prognostic factor for OS (hazard ratio 2.676; 95% confidence interval, 1.674-4.277; p < 0.001). Conclusions: This study showed that the sumSUV(max) adopted from RECIST 1.1 on pretreatment F-18-FDG PET/CT was significantly correlated with response to treatment, OS, and PFS in patients with SCLC. (C) 2013 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/13909)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.